77 related articles for article (PubMed ID: 3043637)
21. Phase II study of rDNA human alpha-2 interferon in multiple myeloma.
Wagstaff J; Loynds P; Scarffe JH
Cancer Treat Rep; 1985 May; 69(5):495-8. PubMed ID: 4005872
[TBL] [Abstract][Full Text] [Related]
22. [Optimising therapy in patients with haematological malignancies].
Dumontet C
Bull Cancer; 2008 Oct; 95(10):959-62. PubMed ID: 19004726
[TBL] [Abstract][Full Text] [Related]
23. Clinical uses for interferon in the treatment of cancer. A critical review.
Ringenberg QS; Patterson WP
Mo Med; 1988 Jan; 85(1):21-6. PubMed ID: 3277031
[No Abstract] [Full Text] [Related]
24. Immunotherapy: the old and the new.
Oldham RK; Smalley RV
J Biol Response Mod; 1983; 2(1):1-37. PubMed ID: 6196449
[No Abstract] [Full Text] [Related]
25. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
[TBL] [Abstract][Full Text] [Related]
26. [Clinical effect of human lymphoblastoid interferon in patients with multiple myeloma].
Yoshida M; Ohta M; Muroi K; Takeda K; Kitagawa S; Tsuboyama A; Sakamoto S; Miura Y; Mutoh Y
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1394-8. PubMed ID: 6742866
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)].
Ohno R; Kodera Y; Ogura M; Murase T; Emi N; Okumura M; Morishita Y; Nagura E; Minami S; Morishima Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2531-6. PubMed ID: 6594973
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B viral infection.
Thomas HC
Am J Med; 1988 Aug; 85(2A):135-40. PubMed ID: 3136648
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
30. Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders.
Sréter L; Kárteszi M; Fehér J; Lutz D
Acta Med Hung; 1988; 45(3-4):323-8. PubMed ID: 3249659
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study on the effect of human lymphoblastoid interferon in multiple myeloma].
Takeyama H; Yano K; Kataoka T; Yamamoto M; Emi N; Kodera Y; Kawashima K; Ohno R; Yokomaku S; Kobayashi M
Gan To Kagaku Ryoho; 1983 Sep; 10(9):2043-8. PubMed ID: 6614939
[TBL] [Abstract][Full Text] [Related]
32. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
Scolozzi R; Boccafogli A
Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310
[TBL] [Abstract][Full Text] [Related]
33. [Can one reconcile planning and innovation?].
Israël L
Bull Cancer; 1991; 78 Suppl 1():67s-68s. PubMed ID: 1912689
[No Abstract] [Full Text] [Related]
34. Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes.
Zambello R; Chisesi T; Agostini C; Trentin L; Masciarelli M; Gasparotto G; Vespignani M; Casorati G; Foa R; Semenzato G
Clin Exp Immunol; 1987 Oct; 70(1):222-30. PubMed ID: 3121223
[TBL] [Abstract][Full Text] [Related]
35. [Effects of interferon on various malignancies].
Taguchi T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):194-204. PubMed ID: 6696457
[TBL] [Abstract][Full Text] [Related]
36. In vivo models for studying the role of autocrine or paracrine growth factors in hematologic malignancies.
Soma T; Dunbar CE
Exp Hematol; 1995 May; 23(5):385-8. PubMed ID: 7720810
[No Abstract] [Full Text] [Related]
37. Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin.
Hiyoshi M; Hashimoto S; Ota T; Nakao T; Takubo T; Tagawa S; Tatsumi N
Haematologia (Budap); 1997; 28(3):177-80. PubMed ID: 9283919
[TBL] [Abstract][Full Text] [Related]
38. [Introduction of natural interferon-alpha "Sumiferon"].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2800-3. PubMed ID: 3631977
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
[TBL] [Abstract][Full Text] [Related]
40. [Cytogenetics and hematology].
Prieto F; Badía L
Med Clin (Barc); 1983 Sep; 81(8):355-61. PubMed ID: 6358717
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
